Evidence map›Paper›PMID 40936042›Full record

ArticleBiotechnology letters2025

Development of a biotechnological process for the production of recombinant canine interferon-alpha using the baculovirus-insect cell and larvae system.

Maria S Rodriguez, Ignacio Smith, Marcela S Villaverde, Joaquin M Birenbaum, Joaquin Poodts, Federico J Wolman, Alexandra M Targovnik, Maria V Miranda

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria S RodriguezDepartamento de Microbiología, Inmunología, Biotecnología y Genética, Facultad de Farmacia y Bioquímica, Cátedra de Biotecnología, Universidad de Buenos Aires, Junín 956, 1113, Buenos Aires, Argentina.
Ignacio SmithDepartamento de Microbiología, Inmunología, Biotecnología y Genética, Facultad de Farmacia y Bioquímica, Cátedra de Biotecnología, Universidad de Buenos Aires, Junín 956, 1113, Buenos Aires, Argentina.
Marcela S VillaverdeUnidad de Transferencia Genética, Instituto de Oncología "Ángel H. Roffo", Universidad de Buenos Aires, Av. San Martín 5481, 1417, Buenos Aires, Argentina.
Joaquin M BirenbaumDepartamento de Microbiología, Inmunología, Biotecnología y Genética, Facultad de Farmacia y Bioquímica, Cátedra de Biotecnología, Universidad de Buenos Aires, Junín 956, 1113, Buenos Aires, Argentina.
Joaquin PoodtsDepartamento de Microbiología, Inmunología, Biotecnología y Genética, Facultad de Farmacia y Bioquímica, Cátedra de Biotecnología, Universidad de Buenos Aires, Junín 956, 1113, Buenos Aires, Argentina.
Federico J WolmanDepartamento de Microbiología, Inmunología, Biotecnología y Genética, Facultad de Farmacia y Bioquímica, Cátedra de Biotecnología, Universidad de Buenos Aires, Junín 956, 1113, Buenos Aires, Argentina.
Alexandra M TargovnikDepartamento de Microbiología, Inmunología, Biotecnología y Genética, Facultad de Farmacia y Bioquímica, Cátedra de Biotecnología, Universidad de Buenos Aires, Junín 956, 1113, Buenos Aires, Argentina.
Maria V MirandaDepartamento de Microbiología, Inmunología, Biotecnología y Genética, Facultad de Farmacia y Bioquímica, Cátedra de Biotecnología, Universidad de Buenos Aires, Junín 956, 1113, Buenos Aires, Argentina. mvic@ffyb.uba.ar.ORCID http://orcid.org/0000-0003-0862-2122

Funding

conicet PIP 2021UBA UBACYT 2020
6 · The paper itself

Abstract

Currently, Latin America is experiencing a considerable increase in demand for veterinary products to ensure animal health. In particular, interferons (IFNs) are cytokines that play an important role in small animal clinics for the treatment of viral or oncological diseases. We developed a biotechnological process for the production of recombinant canine interferon CaIFN-α7 (rCaIFN-α7) using the baculovirus-insect cell and larvae system, and evaluated its biological activity, both antiviral and antitumor, for comparison with the veterinary interferon available on the market, feline omega interferon (rFeIFN-ω, Virbagen Omega®). Recombinant rCaIFN-α7 expressed in Sf9 cell culture was purified in a single step by immobilized metal ion chromatography, yielding 4.43 mg/l with 95% purity. The purified rCaIFN-α7 showed antiviral activity against the canine kidney cell line MDCK (NBL-2, Madin Darby canine kidney) derived from Canis lupus familiaris kidney (ATCC NBL-2) infected with Vesicular Stomatitis Virus (VSV, New Jersey strain), with a recovery of 5.34 × 10

Indexed as

BaculoviridaeInterferon-alphaAnimalsAntineoplastic AgentsAntiviral AgentsBiotechnologyCell LineCell Line, TumorDogsLarvaMadin Darby Canine Kidney CellsRecombinant ProteinsSf9 CellsAntineoplastic AgentsAntiviral AgentsInterferon-alphaRecombinant ProteinsAnimal healthBaculovirus expressionCanine interferon-alphaInsect larvae

Identifiers

PMID40936042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.